Windlas Biotech Limited has announced its financial results for the quarter and nine months ended December 31, 2025. The company reported a significant year-on-year (YoY) revenue growth of 19% for the nine-month period (9MFY26), with revenues from operations reaching ₹666 crore. For the third quarter (Q3FY26), the company achieved a YoY revenue growth of 20%, with revenues from operations amounting to ₹233 crore. This marks the 12th consecutive quarter of record revenue for Windlas Biotech. The Generic Formulations CDMO vertical demonstrated robust growth, increasing by 20% in 9MFY26 and 23% in Q3FY26, driven by an expanding customer base, increased wallet share, and new product launches. The Trade Generics & Institutional vertical grew by 18% in 9MFY26 and 7% in Q3FY26, focusing on accessible and affordable medicines for tier-2 and tier-3 towns in India, and leveraging institutional purchase programs. The Exports vertical also showed strong performance, growing by 29% in 9MFY26 and 36% in Q3FY26, with increased penetration into Rest of the World (RoW) and semi-regulated markets. Excluding the impact of ESOP expenses, the company reported an EBITDA of ₹89 crore (13.3% margin) and a Profit After Tax (PAT) of ₹60 crore (9.0% margin) for 9MFY26. For Q3FY26, excluding ESOP expenses, EBITDA stood at ₹32 crore (13.6% margin) and PAT was ₹22 crore (9.6% margin). The reported EBITDA for 9MFY26 was ₹79 crore and PAT was ₹50 crore, while for Q3FY26, reported EBITDA was ₹24 crore and PAT was ₹15 crore. The management highlighted that India's healthcare budget crossing ₹1 lakh crore signals stronger support for health infrastructure and affordable treatments. Windlas Biotech is strategically positioned to leverage estimated sectoral growth opportunities due to its focus on quality manufacturing and scale. The company is committed to strengthening organizational capabilities, deepening customer partnerships, expanding its product portfolio, and reinforcing operational and financial discipline to create sustainable value for all stakeholders.